Professor Jason Roberts
Researcher biography
Professor Jason Roberts is a NHMRC Practitioner Fellow at The University of Queensland, Consultant Clinical Pharmacist at the Royal Brisbane and Women’s Hospital. He is Director of the NHMRC-funded Centre for Research Excellence REDUCE which is based at the University of Queensland Centre for Clinical Research. He serves as Research Chair of UQCCR and is the Infectious Diseases Theme Leader at UQCCR. He is a clinician-scientist with a strong interest in research and his principal research theme is optimization of antibiotic dosing in the critically ill. Prof Roberts has published over 450 published papers and book chapters on this topic, has been awarded over $30 million in grants and (co)supervises 22 higher research degree students.
Prof Roberts was recognised as Australia’s leading researcher in two separate categories, Critical Care and Communicable Diseases, by the Australian’s 2019 Research Magazine.
He has been invited to present his results at major international conferences in critical care, infectious diseases, pharmacy, nephrology, transplant and safety. He has served on the Critical Review Panel for ATS/IDSA Guidelines of HAP, HCAP and VAP and the Australian Therapeutic Guidelines - Antibiotic and the 2021 Surviving Sepsis Guidelines. He is the Past Chair of the Working Group for Antimicrobial Use in ICU for the European Society of Intensive Care Medicine and an Executive Member of the PK/PD Group (EPASG) within the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).
He is Section Editor for the International Journal of Antimicrobial Agents and an Associate Editor of the Journal or Pharmacy Practice and Research, the journal for the Society of Hospital Pharmacists of Australia and an Associate Editor for Pharmacotherapy and Aanesthesiology Pain and Critical Care Medicine journal. He has convened >20 seminars/conferences including being co-convenor for Medicines Management 2013, The National Conference for Society of Hospital Pharmacists of Australia.
He also engages with Industry to perform studies that develop optimised antibiotic dosing regimens that maximise antibiotic efficacy for testing in clinical trials or for use in special patient populations (e.g. critically ill, pneumonia, dialysis).